Anti-t cell antigen-binding molecule for use in combination with angiogenesis inhibitor

Patent metadata

Field	Value
Publication number	US-2023235056-A1
Application number	US-202118010615-A
Country	US
Kind code	A1
Filing date	Jun 18, 2021
Priority date	Jun 19, 2020
Publication date	Jul 27, 2023
Grant date	—

Abstract

The present disclosure provides methods for preventing, alleviating, or treating cytokine release resulting from administration of a VEGF inhibitor or side effects resulting from the cytokine release. To prevent, alleviate, or treat cytokine release or its side effects, the disclosure also provides combination therapies that use a lymphocyte-stimulating pharmaceutical agent, represented by an anti-T cell antigen-binding molecule, with a VEGF inhibitor. Among the anti-T cell antigen-binding molecules, for example, antibodies that recruit T cells as effector cells into tumor tissues are called T cell redirecting antibodies, and are known as means for treating tumors. On the other hand, when systemic cytokine production is stimulated by binding of antibodies to T cells, it is feared that this systemic action will lead to aberrations such as CRS. The present disclosure provides means for alleviating systemic cytokine production, and will enable safer use of anti-T cell antigen-binding molecules in tumor treatment.

First claim

1 . A method for treating cancer comprising, administering an anti-T cell antigen-binding molecule and a vascular epithelial cell growth factor (VEGF) inhibitor to a subject, wherein the method further prevents and/or alleviates and/or treats cytokine release syndrome and/or cytokine release.

2 . The method of claim 1 , wherein the VEGF inhibitor is administered before or simultaneously with administration of the anti-T cell antigen-binding molecule.

3 . The method of claim 1 , wherein the VEGF inhibitor is administered 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day before the administration of the anti-T cell antigen-binding molecule, or on the same day as but before administration of the anti-T cell antigen-binding molecule.

4 . The method of claim 1 , wherein the VEGF inhibitor is selected from the group consisting of an anti-VEGF antigen-binding molecule, an anti-VEGFR1 antigen-binding molecule, an anti-VEGFR2 antigen-binding molecule, a fusion protein comprising a VEGF receptor or a fragment thereof, and a tyrosine kinase inhibitor.

5 . The method of claim 1 , wherein the VEGF inhibitor is selected from the group consisting of Bevacizumab, Ramucirumab, and Aflibercept.

6 . The method of claim 1 , wherein a corticosteroid is not administered before or simultaneously with the administration of the anti-T cell antigen-binding molecule.

7 . The method of claim 1 , wherein a corticosteroid is further administered before, simultaneously with, or after the administration of the anti-T cell antigen-binding molecule.

8 . The method of claim 6 , wherein the corticosteroid is dexamethasone, a pharmaceutically acceptable salt thereof, or a derivative thereof.

9 . The method of claim 1 , wherein the anti-T cell antigen-binding molecule is a bispecific antigen-binding molecule comprising:
(1) a domain comprising an antibody variable region having T cell receptor complex-binding activity; and (2) a domain comprising an antibody variable region having cancer antigen-binding activity.

10 . The method of claim 1 , wherein the anti-T cell antigen-binding molecule is a bispecific antibody comprising:
(1) a domain comprising an antibody variable region having T cell receptor complex-binding activity; (2) a domain comprising an antibody variable region having glypican 3-binding activity; and (3) a domain comprising an Fc region with reduced binding activity towards an Fey receptor.

11 . (canceled)

12 . The method of claim 1 , wherein the cancer treatment is enhanced by the combined administration of the anti-T cell antigen-binding molecule and VEGF inhibitor as compared to when the anti-T cell antigen-binding molecule or the VEGF inhibitor is administered as a single drug.

13 . The method of claim 1 , claim 1 , wherein the cytokine release syndrome is caused by cytokine release from either or both of a non-tumor tissue and a tumor tissue.

14 . The method of claim 13 , wherein the tumor tissue comprises GPC3-expressing cells.

15 . A method for preventing, alleviating and/or treating cytokine release syndrome or cytokine release comprising, administering a vascular epithelial cell growth factor (VEGF) inhibitor to a subject.

16 . The method of claim 15 , wherein the VEGF inhibitor is selected from the group consisting of an anti-VEGF antigen-binding molecule, an anti-VEGFR1 antigen-binding molecule, an anti-VEGFR2 antigen-binding molecule, a fusion protein comprising a VEGF receptor or a fragment thereof, and a tyrosine kinase inhibitor.

17 . The method of claim 15 , wherein the VEGF inhibitor is selected from the group consisting of Bevacizumab, Ramucirumab, and Aflibercept.

18 . The method of claim 15 , which is for treatment of cancer.

19 . The method of claim 15 , wherein the VEGF inhibitor is administered in combination with cancer immunotherapy.

20 . The method of claim 19 , wherein the VEGF inhibitor is administered before or simultaneously with the cancer immunotherapy.

21 . The method of claim 18 , wherein the VEGF inhibitor is administered 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day before the administration of the cancer immunotherapy.

22 . The method of claim 19 , wherein the cancer immunotherapy is the administration of an anti-T cell antigen-binding molecule, a Chimeric Antigen Receptor expressing T cell (CAR-T cell), or an immune checkpoint inhibitor.

23 . The method of claim 19 , wherein the administered bispecific anti-T cell antigen-binding molecule comprises:
(1) a domain comprising an antibody variable region having T cell receptor complex-binding activity; and (2) a domain comprising an antibody variable region having cancer antigen-binding activity.

24 . The method of claim 19 , wherein the administered bispecific anti-T cell antigen-binding molecule comprises:
(1) a domain comprising an antibody variable region having T cell receptor complex-binding activity; (2) a domain comprising an antibody variable region having cancer antigen-binding activity; and (3) a domain comprising an Fc region with reduced binding activity towards an Fey receptor.

25 . The method of claim 15 , wherein the VEGF inhibitor is administered in combination with a corticosteroid.

26 . The method of claim 19 , wherein the VEGF inhibitor is administered in combination with cancer immunotherapy and a corticosteroid.

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Tanaka Takayoshi
• Sano Yuji
• Kawai Yumiko

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/573

  substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title

• C07K16/2863

  against receptors for growth factors, growth regulators · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61K38/179

  for growth factors; for growth regulators · CPC title